0.10Open0.10Pre Close0 Volume420 Open Interest5.00Strike Price0.00Turnover141.22%IV40.46%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0637Delta0.0404Gamma82.30Leverage Ratio-0.0073Theta-0.0004Rho-5.24Eff Leverage0.0027Vega
Delcath Systems Stock Discussion
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
Delcath Systems Receives Permanent J-Code For HEPZATO
Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma
No comment yet